Studies on Chemotherapy in the Antituberculous Drug-resistant Tuberculosis

Rapid impact of effective chemotherapy on transmission of drug-resistant tuberculosis: pity the guinea pig.

Molecular investigation of resistance to the antituberculous drug ethionamide in multidrug-resistant clinical isolates of Mycobacterium tuberculosis.

Ethionamide (ETH) needs to be activated by the mono-oxygenase EthA, which is regulated by EthR, in order to be active against Mycobacterium tuberculosis. The activated drug targets the enzyme InhA, which is involved in cell wall biosynthesis. Resistance to ETH has been reported to result from various mechanisms, including mutations altering EthA/EthR, InhA and its promoter, the NADH dehydrogena...

Extensively drug-resistant tuberculosis.

Extensively drug-resistant (XDR) tuberculosis is defined as disease caused by Mycobacterium tuberculosis with resistance to at least isoniazid and rifampicin, any fluoroquinolone, and at least one of three injectable second-line drugs (amikacin, capreomycin, or kanamycin). The definition has applicable clinical value and has allowed for more uniform surveillance in varied international settings...

Drug Resistant Tuberculosis

Drug resistant tuberculosis (DRTB) has hit the tuberculosis control programs like a thunderbolt. It has challenged all the aspects of tuberculosis management, from diagnosis till prognosis. India has had a major contribution in DR TB worldwide, with Mumbai city being the niche for DRTB strains. DRTB has emerged distinctly as a “Creation of mankind” than solely as a “Weapon of God” to curtail th...

Drug-resistant tuberculosis in Africa.

Africa has the highest incidence rate per capita of tuberculosis, although the rate varies among the African countries from 17.8% in Cameroon to 70% in Botswana, Zambia, and Zimbabwe. Nevertheless, the levels of drug resistance are relatively low, compared to countries like Russia and Estonia. Because treatment of MDR TB is beyond the reach of most African countries, prevention of the developme...